Phase I Study of TERT DNA and Electroporation With and Without IL-12 DNA for Patients With Breast, Lung, or Pancreatic Cancer at High Risk of Relapse Post Definitive Surgery and Adjuvant Therapy

Trial Profile

Phase I Study of TERT DNA and Electroporation With and Without IL-12 DNA for Patients With Breast, Lung, or Pancreatic Cancer at High Risk of Relapse Post Definitive Surgery and Adjuvant Therapy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs INO 1400 (Primary) ; INO 9012
  • Indications Breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Lung cancer; Ovarian cancer; Pancreatic cancer
  • Focus Adverse reactions; First in man
  • Sponsors Inovio Pharmaceuticals
  • Most Recent Events

    • 10 Nov 2017 Interim results presented at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting 2017, according to an Inovio Pharmaceuticals media release.
    • 10 Jun 2017 Biomarkers information updated
    • 14 Jun 2016 Planned End Date changed from 1 Dec 2016 to 1 Apr 2018, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top